Prosecution Insights
Last updated: April 19, 2026

Nacuity Pharmaceuticals Inc.

6 pending office actions

Portfolio Summary

6
Total Pending OAs
4
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18770850 METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES BONAPARTE, AMY C 1692 Final Rejection Jul 12, 2024
18678550 METHOD FOR PREPARATION OF N-ACETYL CYSTEINE AMIDE OR DI- N-ACETYL CYSTEINE AMIDE AND DERIVATIVES BONAPARTE, AMY C 1692 Final Rejection May 30, 2024
18597021 Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress ROBINSON, MIKHAIL O'DONNEL 1627 Final Rejection Mar 06, 2024
18347896 Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress ROBINSON, MIKHAIL O'DONNEL 1627 Final Rejection Jul 06, 2023
17339652 TREATMENT OF CYSTINOSIS KWON, JOHN SEUNGJAI 1615 Non-Final OA Jun 04, 2021
17156560 PRODRUG FOR THE TREATMENT OF DISEASE AND INJURY OF OXIDATIVE STRESS KWON, JOHN SEUNGJAI 1615 Non-Final OA Jan 23, 2021

Managing Nacuity Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month